Open AccessEffects of protease inhibitors on replication of various myxoviruses
Author(s) -
Mitsuaki Hosoya,
S Matsuyama,
Masanori Baba,
Hitoshi Suzuki,
Shirô Shigeta
Publication year - 1992
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.36.7.1432
Subject(s) - virus , protease , virology , biology , protease inhibitor (pharmacology) , hemagglutinin (influenza) , viral replication , microbiology and biotechnology , aprotinin , leupeptin , influenza a virus , paramyxoviridae , enzyme , viral disease , medicine , biochemistry , viral load , antiretroviral therapy , surgery
We studied the effects of eight protease inhibitors on the multicycle replications of various orthomyxoviruses and paramyxoviruses. Among the compounds, nafamostat mesilate, camostat mesilate, gabexate mesilate, and aprotinin, which are widely used in the treatment of pancreatitis, inhibited influenza virus A and B replication at concentrations that were significantly lower than their cytotoxic thresholds in vitro. None of the protease inhibitors had activity against respiratory syncytial virus, measles virus, or parainfluenza virus type 3 at the highest concentrations tested. Camostat mesilate was found to be the most selective inhibitor. Its 50% effective concentration for influenza virus A replication was 2.2 micrograms/ml, and the selectivity index, which was based on the ratio of the 50% inhibitory concentration for host cell proliferation to the 50% effective concentration for influenza virus A replication, was 680. When the in ovo antiviral activity of the compounds was tested by using chicken embryos, camostat mesilate at a dose of 10 micrograms/g markedly reduced the hemagglutinin titers of influenza viruses A and B.